top of page

業績（2023年）

Publications

  1. Sasaki Y, Murai S, Okamura R, Uesugi Y, Shimada S, Watanuki M, Fujiwara S, Kawaguchi Y, Arai N, Yanagisawa K, Honma M, Yamochi T, Hattori N. CD5- and CD10-positive MYC and BCL2 double-expressor diffuse large B-cell lymphoma with MYD88L265P mutation: a case report and literature review. Rinsho Ketsueki. 2023;64(1):42-48. Japanese. doi: 10.11406/rinketsu.64.42. PMID: 36775306

  2. Yonezawa R, Shimamoto K, Kabasawa N, Sano M, Tanaka S, Matsui M, Harada H, Sunaga T. A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma. Leuk Res Rep. 2023 Feb 25;19: 100365. doi: 10.1016/j.lrr.2023.100365. PMID: 36941843

  3. Suzuki A, Yamaguchi F, Maeda M, Hashiguchi M, Kabasawa N, Sasaki J, Sato T, Fuyama M, Yamazaki Y, Endo K, Iwata K, Kobayashi S, Fujihara H. Antimicrobial Stewardship Program for Patients in the Hematological Department Receiving Carbapenem Therapy: A Single-Center and Interrupted Time Series Analysis. Antibiotics (Basel). 2023 Feb 2; 12(2): 302. doi: 10.3390/antibiotics12020302. PMID: 36830213

  4. Baba Y, Sakai H, Kabasawa N, Harada H. Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy. Intern Med. 2023 Feb 15; 62(4): 613-616. doi: 10.2169/internalmedicine.9812-22. PMID: 35871596

  5. Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, Sakaida E, Saito M, Okamura T, Ito T, Hattori N, Higasa S, Suzuki N, Seki Y, Nogami K. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost. 2023 Mar;21(3):534-545. doi: 10.1016/j.jtha.2022.10.004. PMID: 36696195

  6. Baba Y, Nakamaki T, Sakai H, Fukuchi K, Kabasawa N, Hattori N, Harada H. Chronic neutrophilic leukemia preceded by myelodysplastic syndromes. Int J Hematol. 2023 Nov; 118(5): 636-641. doi: 10.1007/s12185-023-03636-5. PMID: 37439996

bottom of page